Interferon-free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health
Tóm tắt
The efficacy and safety of interferon-free therapies for hepatitis C virus (HCV) infection have been reported. Considering the accumulating evidence for a direct central nervous system infection by HCV, we aim to evaluate the effect of direct acting antivirals (DAA) therapy on cognitive function in HCV patients. We conducted a longitudinal analysis of the cognitive performance of 22 patients (8 HCV+, 14 HCV+/HIV+) who completed neuropsychological testing at baseline and at week 12 after DAA therapy. In 20 patients, we analyzed specific attention parameters derived from an experimental testing based on the Theory of Visual Attention (TVA). Depression, fatigue, and mental health were assessed as patient reported outcomes. At baseline, 54.5% of the patients met the criteria for cognitive impairment and 40% showed impairment in TVA parameters. Follow-up analysis revealed significant improvements in the domains of visual memory/learning, executive functions, verbal fluency, processing speed, and motor skills but not in verbal learning and attention/working memory. We did not observe significant improvement in visual attention measured by TVA. Fatigue and mental health significantly improved at follow-up. Our findings indicate that successful DAA treatment leads to cognitive improvements in several domains measured by standard neuropsychological testing. The absence of improvement in TVA parameters and of significant improvement in the domain of attention/working memory might reflect the persistence of specific cognitive deficits after HCV eradication. In summary, DAA treatment seems to have a positive effect on some cognitive domains and leads to an improvement in mental health and fatigue in HCV-infected patients.
Tài liệu tham khảo
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, Investigators I (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889–1898
Anderson AM, Fennema-Notestine C, Umlauf A, Taylor MJ, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Letendre SL, Group C (2015) CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neuro-Oncol 21:559–567
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799
Aschenbrenner A, Tucha O, Lange K (2001) RWT: Regensburger Wortflüssigkeits-Test. Hogrefe, Göttingen
Bäumler G (1985) Farbe-Wort-Interferenztest (FWIT) nach J. R. Stroop (FWIT). Hogrefe, Göttingen
Beck AT, Steer RA, Brown GK (2000) Beck Depression Inventory-Fast Screen for medical patients: manual. Psychological Corporation, San Antonio
Bladowska J, Knysz B, Zimny A, Małyszczak K, Kołtowska A, Szewczyk P, Gąsiorowski J, Furdal M, Sąsiadek MJ (2014) Value of perfusion-weighted MR imaging in the assessment of early cerebral alterations in neurologically asymptomatic HIV-1-positive and HCV-positive patients. PLoS One 9:e102214
Boneau CA (1960) The effects of violations of assumptions underlying the test. Psychol Bull 57:49–64
Brickenkamp R, Schmidt-Atzert L, Liepmann D (2010) d2R test d2—revision. Hogrefe, Göttingen
Bublak P, Redel P, Sorg C, Kurz A, Förstl H, Müller HJ, Schneider WX, Finke K (2011) Staged decline of visual processing capacity in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 32:1219–1230
Bundesen C (1990) A theory of visual attention. Psychol Rev 97:523–547
Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, Lenkinski R, Afdhal NH (2012) Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol 56:549–556
Cattie JE, Letendre SL, Woods SP, Barakat F, Perry W, Cherner M, Umlauf A, Franklin D, Heaton RK, Hassanein T, Grant I, Group TMARCT (2014) Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment. J Neuro-Oncol 20:561–570
Dirks M, Pflugrad H, Haag K, Tillmann HL, Wedemeyer H, Arvanitis D, Hecker H, Tountopoulou A, Goldbecker A, Worthmann H, Weissenborn K (2017) Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?! J Viral Hepat 24:541–550
Dyrholm M, Kyllingsbæk S, Espeseth T, Bundesen C (2011) Generalizing parametric models by introducing trial-by-trial parameter variability: the case of TVA. J Math Psychol 55:416–429
Finke K, Bublak P, Dose M, Müller HJ, Schneider WX (2006) Parameter-based assessment of spatial and non-spatial attentional deficits in Huntington’s disease. Brain 129:1137–1151
Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA (2012) Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 142:634–643.e6
Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD (2001) Evidence for a cerebral effect of the hepatitis C virus. Lancet 358:38–39
Forton DM, Hamilton G, Allsop JM, Grover VP, Wesnes K, O'Sullivan C, Thomas HC, Taylor-Robinson SD (2008) Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol 49:316–322
Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M (1998) Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51:1171–1178
Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, Younossi ZM (2016) Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 14:156–64.e3
Grover VP, Pavese N, Koh SB, Wylezinska M, Saxby BK, Gerhard A, Forton DM, Brooks DJ, Thomas HC, Taylor-Robinson SD (2012) Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat 19:e89–e96
Habekost T, Petersen A, Vangkilde S (2014) Testing attention: comparing the ANT with TVA-based assessment. Behav Res Methods 46:81–94
Hammoud DA, Endres CJ, Chander AR, Guilarte TR, Wong DF, Sacktor NC, McArthur JC, Pomper MG (2005) Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neuro-Oncol 11:346–355
Helmstaedter C, Lendt M, Lux S (2001) VLMT Verbaler Lern- und Merkfähigkeitstest. Göttingen, Beltz Test
Hinkin CH, Castellon SA, Levine AJ, Barclay TR, Singer EJ (2008) Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis 27:11–17
Horn W (1983) Leistungsprüfsystem L-P-S. 2., erweiterte und verbesserte Auflage. Hogrefe, Göttingen
Huckans M, Fuller B, Wheaton V, Jaehnert S, Ellis C, Kolessar M, Kriz D, Anderson JR, Berggren K, Olavarria H, Sasaki AW, Chang M, Flora KD, Loftis JM (2015) A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res 78:184–192
Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H, Schmutz G, Wehmeyer MH, Boesecke C, Simon KG, Berger F, Rockstroh JK, Zur Wiesch JS, Baumgarten A, Mauss S (2016) Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01). Clin Infect Dis 63:1320–1324
Ishihara S (1976) Tests for colour-blindness (24 plates ed.). Kanehara Shuppan Co., Ltd., Tokyo
Kleefeld F, Heller S, Jessen H, Ingiliz P, Kraft A, Hahn K (2017) Effect of interferon-free therapy on cognition in HCV and HCV/HIV infection: a pilot study. Neurology 88:713–715
Kraft A, Irlbacher K, Finke K, Kaufmann C, Kehrer S, Liebermann D, Bundesen C, Brandt SA (2015) Dissociable spatial and non-spatial attentional deficits after circumscribed thalamic stroke. Cortex 64:327–342
Kraus MR, Schäfer A, Teuber G, Porst H, Sprinzl K, Wollschläger S, Keicher C, Scheurlen M (2013) Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology 58:497–504
Kuhn T, Sayegh P, Jones JD, Smith J, Sarma MK, Ragin A, Singer EJ, Albert Thomas M, Thames AD, Castellon SA, Hinkin CH (2017) Improvements in brain and behavior following eradication of hepatitis C. J Neuro-Oncol 23:593–602
Majer M, Welberg LA, Capuron L, Miller AH, Pagnoni G, Reeves WC (2008) Neuropsychological performance in persons with chronic fatigue syndrome: results from a population-based study. Psychosom Med 70:829–836
Marcellin F, Protopopescu C, Poizot-Martin I, Miailhes P, Esterle L, Wittkop L, Spire B, Bocquier A, Salmon-Ceron D, Dabis F, Carrieri MP, Group HACS (2016) Short article: fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). Eur J Gastroenterol Hepatol 28:1003–1007
Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ (2011) Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Int 31:1028–1038
Pflugrad H, Meyer GJ, Dirks M, Raab P, Tryc AB, Goldbecker A, Worthmann H, Wilke F, Boellaard R, Yaqub M, Berding G, Weissenborn K (2016) Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction. J Viral Hepat 23:348–357
Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, Rakela J, Laskus T (2002) Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 76:600–608
Reichenberg A, Gorman JM, Dieterich DT (2005) Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 19(Suppl 3):S174–S178
Reitan R (1979) Trail Making Test. Arizona, Reitan Neuropsychology Laboratory
Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J (2014) Validation of the Fatigue Severity Scale in chronic hepatitis C. Health Qual Life Outcomes 12:90
Strauss E, Sherman EMS, Spreen O (2006) A compendium of neuropsychological tests: administration, norms, and commentary. Oxford University Press, New York
Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM, Group H-TS (2016) Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150:419–429
Thames AD, Castellon SA, Singer EJ, Nagarajan R, Sarma MK, Smith J, Thaler NS, Truong JH, Schonfeld D, Thomas MA, Hinkin CH (2015) Neuroimaging abnormalities, neurocognitive function, and fatigue in patients with hepatitis C. Neurol Neuroimmunol Neuroinflamm 2:e59
Thein HH, Maruff P, Krahn MD, Kaldor JM, Koorey DJ, Brew BJ, Dore GJ (2007) Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med 8(8):520–528
Tillmann HL (2014) Hepatitis C virus infection: when is a cure not a cure? J Infect Dis 209:6–8
Trites R (2002) Grooved Pegboard test user instructions. Lafayette, Lafayette Instrument Company
Tully DC, Hjerrild S, Leutscher PD, Renvillard SG, Ogilvie CB, Bean DJ, Videbech P, Allen TM, McKeating JA, Fletcher NF (2016) Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients. Liver Int 36:1418–1424
Vangkilde S, Bundesen C, Coull JT (2011) Prompt but inefficient: nicotine differentially modulates discrete components of attention. Psychopharmacology 218:667–680
Vivithanaporn P, Nelles K, DeBlock L, Newman SC, Gill MJ, Power C (2012) Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. J Neurol Sci 312:45–51
von Aster M, Neubauer A, Horn R (2006a) Zahlennachsprechen in: Wechsler Intelligenztest für Erwachsene (WIE). Pearson, Frankfurt am Main
von Aster M, Neubauer A, Horn R (2006b) Zahlen-Symbol-Test (Kodierung) in: Wechsler Intelligenztest für Erwachsene (WIE). Pearson, Frankfurt am Main
von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, Kücükköylü S, Köller H, Haslinger BA, Oette M, Arendt G (2004) Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr 35:131–137
Ware J, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233
Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schüler A, Ennen JC, Ahl B, Manns MP, Böker KW (2004) Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 41:845–851
Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Nader F, Hunt S (2014) Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 60:741–747